Analytes/procedures in
bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).
Program FL9 is intended for laboratories that perform measurable residual disease (MRD) testing (rare event analysis) for plasma cell myeloma.
Participation in this program alone does not satisfy PT requirements for laboratories performing more general analysis of leukemia/lymphoma specimens.
Program Information
- Two 4.5‑mL specimens containing a cell line/whole blood mixture simulating plasma cell myeloma measurable residual disease
- One online case consisting of gated dot plots
This program has stability of two days or less. The CAP cannot guarantee performance or offer credits for orders placed for shipment outside of the US and Canada.
Shipping Schedule
- Shipment A: May 20
- Shipment B: December 2
Help